Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04634825
Title Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MacroGenics

hypopharynx cancer

laryngeal squamous cell carcinoma

oropharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma


MGA271 + Retifanlimab

MGA271 + MGD013

Age Groups: adult | senior
Covered Countries USA | ESP

No variant requirements are available.